Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 13, 2026Blood ResearchOpen Access

Infectious complications after CAR T-cell therapy: mechanisms, risk stratification, and prevention

View Full Paper
Ask AI
Bookmark
Share

Authors

ELE LeeJLJ H LeeHKHye Ryeon Kim

Discussion

Loading...

Member takes

Overview

Review highlights infection mechanisms and prevention strategies in CAR T-cell therapy recipients, suggesting improved outcomes.

Key Points

  • This review aims to summarize the infectious complications and risk factors related to CAR T-cell therapy, alongside preventive strategies.
  • Analysis of infection patterns post-CAR T-cell infusion
  • Evaluation of current guidelines and evidence regarding infectious risk and prevention
  • Discussion of individualized prophylaxis approaches based on patient and therapy characteristics.
  • Infections primarily occur in early post-infusion, with bacterial infections being most common initially, and viral/opportunistic infections becoming prominent later.
  • BCMA-directed CAR T-cell therapy is linked to higher infection rates due to plasma cell depletion and impaired humoral immunity.
  • Effective prevention strategies include antiviral prophylaxis, immunoglobulin replacement, and coordinated risk-adapted approaches.

Cite This Study

Lee et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf4dafaef96ed7f05709fhttps://doi.org/10.1007/s44313-026-00145-2
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Severe infections after CD19-directed chimeric antigen receptor T-cell therapy for Relapsed/Refractory large B-cell lymphoma, a retrospective real-life study from the DESCAR-T registry (LYSA)2025
  2. 2Prevalence and mortality of infections following CAR T-cell therapy in children, adolescents, and young adults: A systematic review and meta-analysis2025
  3. 3Infectious Complications Following CD30 Chimeric Antigen Receptor T-cell Therapy in Adults.2025 · 1 citations
  4. 4Chimeric Antigen Receptor Immunotherapy for Infectious Diseases: Current Advances and Future Perspectives2025 · 7 citations
  5. 5Comparative analysis of severe infection risk and survival outcomes in DLBCL patients treated with CAR T-cell therapy versus standard chemoimmunotherapy: Insights from real-world data2025